Advancing injectable therapy in adults with T2D: Findings from the SoliMix trial
MORE INFORMATION HERE 18:30 – 18:35 Symposium introduction Julio Rosenstock (USA) 18:35 – 18:55 Glycemic goals and overcoming barriers: Unmet needs for people with T2D
MORE INFORMATION HERE 18:30 – 18:35 Symposium introduction Julio Rosenstock (USA) 18:35 – 18:55 Glycemic goals and overcoming barriers: Unmet needs for people with T2D
Chair: Pratik Choudhary (UK) Faculty: Bernhard Gehr (DE), Hood Thabit (UK) 20:00 – 20:10 Welcome and introduction Pratik Choudhary (UK) 20:10 – 20:25 The complexities
18:30 – 18:31 Welcome Athena Philis-Tsimikas (USA)Simon Heller (UK) 18:31 – 18:35 A retrospective look:100 years since insulin was discovered Simon Heller (UK) 18:35 –
20:00 – 20:06 Evaluation of the incretin effect in humans Laerke Gasbjerg (DNK) 20:06 – 20:12 Contribution of GLP-1 to the incretin effect Filip Knop
19:30 – 19:40 Review the role of incretin hormones in physiology and type 2 diabetes pathophysiology Juan Pablo Frias (USA) 29.09.2021 19:30 – 19:40 Moscow
Speaker: Michael Nauck (GER) 19:15 – 19:25 Michael Nauck talks about the incretin journey: from past research, to current understandings, to where the field could
08:45 – 08:46 Speaker Introduction Jacek Kiljanski (Lilly, POL) 08:46 – 08:54 Featuring Incretin Biology and Type 2 Diabetes Animated Video Tina Vilsbøll (DNK) 08:54
Speakers: Merlin Thomas (AUS) Silvio Inzucchi (USA) Francesco Giorgino (ITA) The content for empagliflozin contained in this virtual session is intended for delegates from
Speakers: Paola Fioretto (ITA) Roland Schmieder (GER) Samy Hadjadj (FRA) 29.09.2021 19:45 – 20:45 Meet the Expert
Chair: Paola Fioretto (ITA) 18:30 –18:35 Welcome and introductions Paola Fioretto (ITA) 18:35 – 18:45 Addressing unmet needs in CKD and T2D with nonsteroidal MR
